Leo Pharma

Leo Pharma A/S

Type	Aktieselskab A/S Danish Public Limited stock based corporation
Industry	Pharmaceutical industry
Founded	1908
Founder	August Kongsted and Anton Antons
Headquarters	Ballerup, Copenhagen, Denmark
Area served	Worldwide
Key people	Gitte Aabo (CEO)
Products	Prescription drugs for dermatology, bone remodeling thrombosis and coagulation
Revenue	7.973 billion DKK (2014)^[1]
Total assets	31.627 billion DKK (2014)^[1]
Number of employees	4,712 (2014)^[1]
Website	Home Page
Footnotes / references Wholly owned by a foundation (nonprofit)

Leo Pharma A/S is a multinational Danish pharmaceutical company, founded in 1908, with a presence in about 100 countries. Its headquarters are in Ballerup, near Copenhagen^[2] The company is 100% integrated into a private foundation owned by the LEO Foundation.^[3] Leo Pharma develops and markets products for dermatology, bone remodeling thrombosis and coagulation.^[4] In 1945 it was the first producer of penicillin outside the USA and UK.

History

Formation & the 20th Century

In 1908, pharmacists August Kongsted and Anton Antons bought the LEO Pharmacy in Copenhagen, Denmark. With the purchase, they established 'Københavns Løveapoteks kemiske Fabrik', today known as LEO Pharma. LEO Pharma celebrated its centennial in 2008. Flags bearing the LEO logo were flying in every country where LEO products are available, more than a hundred flags in total. Today, LEO Pharma has an ever growing pipeline with over 4,800 specialists focussing on dermatology and thrombosis.

1912 – The company launched its own Aspirin headache tablet
1917 – The company exported Denmarks first drug, Digisolvin
1940 – The company launched its own Heparin product.
1958-08-13 - Patent filed for Bendrofluazide.^[5]
1962 – The company launched Fucidin to be used to treat staphylococcus infections

21st Century & onwards

In 2015, the company announced it would acquire Astellas Pharmas dermatology business for $725 million.^[6]

References

This article is issued from Wikipedia - version of the 11/2/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.